Research Article
[Retracted] The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis
Table 1
Articles included in the study.
| | Author | Year published | Phase | Stage | Total | t1 | t2 | Mutation |
| | Wu et al. [11] | 2015 | III | IIIB/IV | 217 | Erlotinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Rosell et al. [12] | 2012 | III | III/IV | 174 | Erlotinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Gridelli et al. [13] | 2012 | III | IIIB/IV | 39 | Erlotinib | CTX | Exon 19 deletion mutation | | Chen et al. [14] | 2012 | NA | IIIB/IV | 116 | Erlotinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Wu et al. [15] | 2013 | III | IIIB/IV | 97 | Erlotinib | CTX | Exon 19 deletion, or G719X, L858R, or L861Q mutation | | Han et al. [16] | 2012 | III | IIIB/IV | 42 | Gefitinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Mok et al. [17] | 2009 | III | IIIB/IV | 261 | Gefitinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Maemondo et al. [18] | 2010 | NA | IIIB/IV | 228 | Gefitinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Mitsudomi et al. [19] | 2010 | III | IIIB/IV | 177 | Gefitinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Han et al. [20] | 2017 | II | IIIB/IV | 121 | Gefitinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Patil et al. [21] | 2017 | III | IIIB/IV | 290 | Gefitinib | CTX | Exon 19 deletion or exon 21 L858R mutation | | Sequist et al. [22] | 2013 | III | IIIB/IV | 345 | Afatinib | CTX | Exon 19 deletion or exon 21 L858R mutation or others | | Wu et al. [23] | 2014 | III | IIIB/IV | 364 | Afatinib | CTX | Leu858Arg, exon 19 deletions, or other | | Lynch et al. [24] | 2010 | III | IIIB/IV | 676 | Cetuximab | CTX | N/A | | Pirker et al. [25] | 2009 | III | IIIB/IV | 748 | Cetuximab | CTX | N/A | | Shi et al. [26] | 2017 | III | IIIB/IV | 285 | Icotinib | CTX | Exon 19/21 EGFR mutations |
|
|
